Newtyn Management’s Q32 Bio QTTB Stock Holding History

Newtyn Management’s Portfolio QTTB Stock Details QTTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-77,737	Closed	-$851K	–	47
2023 Q4	$851K	Buy	+77,737	New	+$1.14M	0.17%	38

Other funds holding QTTB

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Temasek Holdings

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Newtyn Management's QTTB Position: Q1 2024 in Review

Newtyn Management sold out of Q32 Bio (QTTB) in Q1 2024, closing a stake of 77,737 shares — an estimated $851K sold.

Newtyn Management first reported a position in QTTB in Q4 2023 and held it in 1 quarter. The position peaked at $851K in Q4 2023. 39 funds tracked by Wall St. Rank hold QTTB as of Q1 2024.

Newtyn Management reported no remaining Q32 Bio position as of Q1 2024 after selling out during the quarter.
Newtyn Management sold 77,737 Q32 Bio shares in Q1 2024, an estimated $851K.
Newtyn Management first reported a position in Q32 Bio in Q4 2023 and held it in 1 quarter.
Newtyn Management's Q32 Bio position peaked at $851K in Q4 2023.
39 funds tracked by Wall St. Rank held Q32 Bio as of Q1 2024.

Based on Newtyn Management's 13F filing for Q1 2024, filed 15 May 2024.